Escherichia coli infection
disease diseaseOn this page
Also known as Bacterial infection caused by E. coliBacterial infection due to E. coliColibacillosisE COLI INFECTE coli InfectionE coli InfectionsE coli infections, recurrentE. coli InfectionE. coli InfectionsESCHERICHIA COLI INFECTEscherichia coli InfectionsINFECT E COLIINFECT ESCHERICHIA COLIInfection caused by Escherichia coliInfection due to Escherichia coliInfection, E coliInfection, E. coliInfection, Escherichia coliInfections, E coli
Summary
Escherichia coli infection (MONDO:0020920) is a disease with 4 GWAS associations across 8 studies and 26 clinical trials. Top therapeutic interventions include ertapenem, piperacillin, and cefotetan. A subtype of bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 4
- Clinical trials: 26
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | escherichia coli infection |
| Mondo ID | MONDO:0020920 |
| EFO | EFO:1001318 |
| MeSH | D004927 |
| NCIT | C34594 |
| SNOMED CT | 71057007 |
| UMLS | C0014836 |
| MedGen | 4543 |
| Is cancer (heuristic) | no |
Also known as: Bacterial infection caused by E. coli · Bacterial infection due to E. coli · Colibacillosis · E COLI INFECT · E coli Infection · e coli infection · E coli Infections · E coli infections · E coli infections, recurrent · E. coli Infection · E. coli infection · E. coli Infections · ESCHERICHIA COLI INFECT · escherichia coli infection · Escherichia coli Infections · INFECT E COLI · INFECT ESCHERICHIA COLI · Infection caused by Escherichia coli · Infection due to Escherichia coli · Infection, E coli (+5 more)
Data availability: 4 GWAS associations (8 studies) · 1 HPO phenotype.
Disease family
This is a subtype of bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › escherichia coli infection
Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, chorioamnionitis, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, Pseudomonas infection, septic peritonitis, bacterial infectious disease with sepsis, empyema, bacterial urinary tract infection, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, haemophilus infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, necrotizing soft tissue infection, mycobacterial infectious disease, gram-negative bacterial infections, gram-positive bacterial infections, spirochaetales infections, skin disease caused by bacterial infection, staphylococcal infection, anaerobic bacteria infectious disease, Klebsiella infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease
Subtypes (1): escherichia coli discitis
Genetics & variants
GWAS landscape
4 GWAS associations across 8 studies. Top hits map to 2 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs150520438 | 2e-11 | LMNTD1 | T | 2.75 |
| rs140093730 | 3e-11 | NAV2 | T | 3.3 |
| rs138270150 | 3e-11 | CAPZA3 - RPL7P6 | C | 2.44 |
| rs142397593 | 2e-08 | LINC02872 - DAPK1 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90079566 | Backman JD | 2021 | 3,844 | 384,028 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90083552 | Backman JD | 2021 | 3,844 | 384,028 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90435521 | Zhou W | 2018 | 2,744 | 393,897 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90477041 | Verma A | 2024 | 2,525 | 442,291 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477040 | Verma A | 2024 | 816 | 118,995 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90479746 | Verma A | 2024 | 816 | 118,995 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481429 | Verma A | 2024 | 327 | 58,695 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651529 | Liu TY | 2025 | 101 | 213,110 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 4 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 3 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 3 |
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs150520438 | 12 | 25493828 | T>A,C | 0 | intron_variant | LMNTD1 | 2e-11 | Tier 4: intronic/intergenic |
| rs140093730 | 11 | 19708138 | T>C | 0.001 | intron_variant | NAV2 | 3e-11 | Tier 4: intronic/intergenic |
| rs138270150 | 12 | 18861575 | C>A | 0 | intergenic_variant | CAPZA3 - RPL7P6 | 3e-11 | Tier 4: intronic/intergenic |
| rs142397593 | 9 | 87223577 | G>A | intron_variant | LINC02872 - DAPK1 | 2e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Influenza Virus Vaccine | Phase 3 |
Clinical trials & evidence
Clinical trials
Clinical trials: 26.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 17 |
| PHASE1 | 4 |
| PHASE2 | 2 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03891433 | PHASE4 | SUSPENDED | Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae |
| NCT02729116 | PHASE2/PHASE3 | UNKNOWN | Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients |
| NCT06938867 | PHASE1/PHASE2 | RECRUITING | Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant |
| NCT07318584 | PHASE2 | NOT_YET_RECRUITING | Cefotetan Therapy for Escherichia Coli Infections |
| NCT02537847 | PHASE2 | UNKNOWN | Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli |
| NCT07280598 | PHASE1 | NOT_YET_RECRUITING | Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections |
| NCT00362869 | PHASE1 | TERMINATED | Enteroaggregative E.Coli (EAEC) |
| NCT01382095 | PHASE1 | COMPLETED | Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea |
| NCT01644565 | PHASE1 | COMPLETED | Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea |
| NCT04694235 | Not specified | ACTIVE_NOT_RECRUITING | Egg Intervention During Pregnancy in Indonesia |
| NCT06148480 | Not specified | RECRUITING | Perinatal Transmission of MDR Bacteria |
| NCT00167986 | Not specified | COMPLETED | Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care |
| NCT00167999 | Not specified | COMPLETED | Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units |
| NCT00298103 | Not specified | COMPLETED | Antibiotic Resistant Community-Acquired E. Coli |
| NCT00363220 | Not specified | COMPLETED | Community - Associated Extended-spectrum Beta-lactamases (ESBL) |
| NCT00877708 | Not specified | COMPLETED | Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol |
| NCT01324726 | Not specified | COMPLETED | Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms |
| NCT01406288 | Not specified | COMPLETED | Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 |
| NCT02541695 | Not specified | COMPLETED | Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli |
| NCT02853708 | Not specified | COMPLETED | Epidemiology of ST131 in Besançon University Hospital |
| NCT03303937 | Not specified | COMPLETED | Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients |
| NCT03800147 | Not specified | UNKNOWN | Effects of Nutritional Fat on the Growth of Intestinal E. Coli |
| NCT03869593 | Not specified | TERMINATED | Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria |
| NCT04117113 | Not specified | COMPLETED | Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2) |
| NCT04574596 | Not specified | COMPLETED | Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli |
| NCT06252428 | Not specified | COMPLETED | Detection of Biofilm Among Uropathogenic Escherichia Coli Clinical Isolates in Suez Canal University Hospitals |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ERTAPENEM | 4 | 3 |
| PIPERACILLIN | 4 | 2 |
| CEFOTETAN | 4 | 1 |
| MEROPENEM | 4 | 1 |
| TAZOBACTAM | 4 | 1 |
| SITAFLOXACIN ANHYDROUS | 3 | 4 |
Related Atlas pages
- Drugs: Ertapenem, Piperacillin, Cefotetan, Meropenem, Tazobactam, Sitafloxacin